Compare BioNTech SE - ADR (BNTX) vs Home Depot Inc (HD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Home Depot Inc — how do they compare? BioNTech SE - ADR trades at $92.64 (market cap $23.31B), while Home Depot Inc trades at $354.5 (market cap $349.77B). The key difference: Home Depot Inc is far larger — about 15× BioNTech SE - ADR's market cap, and Home Depot Inc pays a 2.66% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | HD | |
|---|---|---|
Market Cap | $23.31B | $349.77B |
Sector | Health | Consumer Cyclical |
52-Week High | $119.34 | $423.42 |
52-Week Low | $83.89 | $297.51 |
Enterprise Value | $6.60B | $411.32B |
Dividend Yield | — | 2.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $93.67, up 2.72% today, with a bullish technical signal and strong analyst support. The stock faces fundamental challenges, including declining COVID-19 vaccine revenue and negative profitability, but holds a robust cash position of $16.78 billion. Recent news highlights leadership changes and pipeline advancements in oncology, with a consensus price target of $121.00 implying significant upside potential.
Outlook: Long-term growth hinges on oncology pipeline success, but near-term risks from vaccine demand volatility and net losses persist. Investment opportunity lies in discounted valuation relative to cash and pipeline assets, though execution risks and competitive pressures require careful monitoring.
Home Depot (HD) trades at $350.78, down 1.36% on the day, with a bullish technical outlook supported by moving averages and strong institutional support. The company reported $159.51B in revenue for 2025 with solid profitability metrics including 8.41% net margin and 128.38% ROE. Recent earnings show mixed results with Q2 2026 expectations at $4.73 EPS. Analyst consensus remains positive with 59% buy ratings and a $371.25 price target, representing 5.8% upside potential.
The stock presents a compelling long-term opportunity given strong fundamentals and analyst optimism, though near-term headwinds include weakening big-ticket demand and margin pressure from investments. Housing market sensitivity and competitive pressures remain key risks, but Pro business growth and digital initiatives provide resilience. Current valuation at 24.91 P/E appears reasonable for the quality franchise.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Home Depot Inc
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →
